Alterity Therapeutics Raises $20M in Strategic Placement
Ticker: PRNAF · Form: 6-K · Filed: Sep 8, 2025 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Key Dollar Amounts | $20.0 million |
| Sentiment | bullish |
Sentiment: bullish
Topics: financing, biotech, capital-raise
TL;DR
Alterity just snagged $20M to fund their drug pipeline.
AI Summary
Alterity Therapeutics Ltd. announced on September 8, 2025, that it has raised $20.0 million through a strategic placement. This filing incorporates the announcement into its SEC registration statements.
Why It Matters
This capital infusion could support Alterity's ongoing drug development programs, potentially advancing their therapeutic candidates closer to market.
Risk Assessment
Risk Level: medium — The company is a development stage enterprise, indicating significant risk associated with bringing new therapies to market and the inherent volatility of the biotechnology sector.
Key Numbers
- $20.0M — Capital Raised (Funds secured through a strategic placement to support company operations and development.)
Key Players & Entities
- Alterity Therapeutics Ltd. (company) — Registrant and issuer of the filing
- $20.0 million (dollar_amount) — Amount raised in strategic placement
- September 2025 (date) — Reporting period for the Form 6-K
- Prana Biotechnology Ltd (company) — Former name of Alterity Therapeutics Ltd.
FAQ
What is the purpose of this Form 6-K filing?
This Form 6-K is being incorporated by reference into Alterity Therapeutics Ltd.'s existing Registration Statements on Form S-8 and Form F-3.
When was the strategic placement announced?
The strategic placement, raising $20.0 million, was announced in an exhibit (99.1) submitted with this Form 6-K, which is for the month of September 2025.
What is Alterity Therapeutics Ltd.'s former name?
Alterity Therapeutics Ltd.'s former name was Prana Biotechnology Ltd, with a date of name change on January 5, 2001.
Where is Alterity Therapeutics Ltd. headquartered?
Alterity Therapeutics Ltd.'s principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Does Alterity Therapeutics Ltd. file annual reports under Form 20-F?
Yes, Alterity Therapeutics Ltd. indicates it files or will file annual reports under cover of Form 20-F.
Filing Stats: 191 words · 1 min read · ~1 pages · Grade level 11.4 · Accepted 2025-09-08 08:00:14
Key Financial Figures
- $20.0 million — are submitted: 99.1 Alterity Raises $20.0 million in Strategic Placement 1 SIGNATURE
Filing Documents
- ea0256345-6k_alterity.htm (6-K) — 14KB
- ea025634501ex99-1_alterity.htm (EX-99.1) — 12KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- 0001213900-25-085289.txt ( ) — 33KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2025 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Alterity Raises $20.0 million in Strategic Placement 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: September 8, 2025 2